Estrella Immunopharma, Inc. (ESLA)
| Market Cap | 18.24M-66.8% |
| Revenue (ttm) | n/a |
| Net Income | -10.01M |
| EPS | -0.25 |
| Shares Out | 43.50M |
| PE Ratio | n/a |
| Forward PE | -1.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,812 |
| Open | 0.41 |
| Previous Close | 0.43 |
| Day's Range | 0.41 - 0.44 |
| 52-Week Range | 0.41 - 3.15 |
| Beta | 0.93 |
| Analysts | none |
| Price Target | 12.00(+2761.91%) |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ESLA
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ESLA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ESLA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ESLA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ESLA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ESLA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical trial related service fee to related party (Note 5) | $1.38M | 67.16% |
| Professional fee | $289.93K | 14.16% |
| Change in fair value of derivative liabilities | $222.09K | 10.85% |
| Stock-based compensation (Note 8) | $145.30K | 7.10% |
| Consulting fee | $15.00K | 0.73% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ESLA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ESLA from public contracts
Source: USAspending.gov
ESLA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ESLA’s recent data — informational, not investment advice